Cytotoxicity News and Research

RSS

A common compound in mouthwashes found to inhibit SARS-CoV-2 in vitro

Researchers found that cetylpyridinium chloride, found in most mouthwashes, lowers infectivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, likely by inhibiting viral fusion with target cells. With more tests to prove validity, mouthwashes could be a simple, cheap way of curbing transmission.

24 Dec 2020

Cross-reactive coronavirus antibodies shape COVID-19 convalescent plasma functionality

The onset of the current COVID-19 pandemic revealed the seventh known pathogenic human coronavirus, SARS-CoV-2.

21 Dec 2020

New screening platform can be used to discover more effective drugs for type 1 diabetes

With nearly 2 million Americans battling type 1 diabetes, it is no surprise that clinical therapies for the disease are constantly evolving and improving.

16 Dec 2020

Traditional herbal medicine Respiratory Detox Shot (RDS) inhibits SARS-CoV, SARS-CoV-2 and Influenza A infection in vitro

As researchers continue to search for antivirals to counter COVID-19, a study presents the potential utility of a decoction called Respiratory Detox Shot (RDS).

16 Dec 2020

Reverse phenotyping shows reactive T cell profiles in SARS-CoV-2 infection

A new study appearing as a preprint on the medRxiv* browser in December 2020 employs reverse phenotyping technology to explore T cell responses in COVID-19.

10 Dec 2020

MEDS433 hinders SARS-CoV-2 replication

A paper that recently appeared in the preprint server bioRxiv* reports the powerful activity of a compound named MEDS433 against this virus.

10 Dec 2020

Amilorides reduce SARS-CoV-2 viral replication in vitro

A new U.S. study published on the bioRxiv preprint server reports the use of an amiloride-based scaffold that targets a viral RNA structure known to be essential in viral replication in the 5’-untranslated region (UTR) of the virus. The researchers say this heralds the application of these molecules as chemical probes to explore viral biology and produce specific antivirals targeting RNA regions of the coronavirus genome.

8 Dec 2020

Virusend TX-10 detergent rapidly reduces SARS-CoV-2 infectivity

Researchers at Liverpool School of Tropical Medicine have conducted a study showing that a novel disinfectant called Virusend TX-10 is highly effective at inactivating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

29 Nov 2020

Female reproductive hormones may be protective against COVID-19

In an article recently published in Trends in Endocrinology & Metabolism, Graziano Pinna from the University of Illinois in Chicago outlines some of the evidence suggesting that female reproductive hormones may play a role in the sex bias that has been observed in coronavirus disease 2019 (COVID-19).

29 Nov 2020

Resveratrol shows potential as SARS-CoV-2 antiviral, study finds

A recent study reveals that resveratrol, a phenolic compound produced by spermatophytes, can inhibit the viral replication SARS-CoV-2.

27 Nov 2020

Biocompatible photooxygenation catalyst could be potentially used to treat amyloid diseases

A new, biocompatible photooxygenation catalyst that can selectively oxygenate and degrade the pathogenic aggregation of Alzheimer's disease (AD)-related amyloid-β peptide (Aβ) under near-infrared (NIR) light irradiation is developed.

25 Nov 2020

Scientists uncover new method to produce compounds with anti-cancer properties

In the past decades, cancer has surpassed many other diseases to become the current second leading cause of death globally, with one in six people dying from it.

17 Nov 2020

Asymptomatic individuals mount polyfunctional antibody response to SARS-CoV-2

Researchers in France have conducted a study showing that people who are asymptomatic following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – elicit a polyfunctional antibody response to the virus.

16 Nov 2020

Antifungal agent Itraconazole inhibits SARS CoV-2 in vitro

Itraconazole is a broad-spectrum antifungal agent that has been shown to have some in vitro activity against SARS-CoV-2 by a team of Belgian and German researchers.

16 Nov 2020

Polymeric nanomicelles effectively deliver anti-cancer drugs to glioblastoma

Using practical nano-DDS technology, a polymeric nanomicelle that effectively delivers the potent mitotic inhibitor desacetyl vinblastine hydrazide (DAVBNH) to glioblastoma (GBM) was developed.

12 Nov 2020

Promising new antivirals target arboviruses and SARS-CoV-2: Nodosome inhibitors

A new study describes two promising small molecules that inhibit a host cell factor, called nucleotide binding oligomerization domain-containing protein 2 (NOD2), that inhibits the replication and spread of many arboviruses. This could lead to the development of broad-spectrum antivirals. The study's findings have been published on the preprint server bioRxiv*.

10 Nov 2020

Novel 3D-printed scaffold loaded with chemotherapy drug could reduce breast cancer recurrence

The recurrence of cancer after surgery is a major concern for patients. New findings from a QUT study have shown the potential for a novel 3D-printed porous scaffold which is loaded with a common chemotherapy drug that can reduce breast cancer recurrence in an experimental setting.

10 Nov 2020

Green tea and some fruit juices inhibit SARS-CoV-2 in vitro

Green tea, chokeberry juice, and pomegranate juice killed flu and SARS-CoV-2 viruses when incubated with the viruses in vitro. Thus, oral rinsing using these might be effective in preventing COVID-19.

5 Nov 2020

Small molecules block SARS-CoV-2 spike-ACE2 attachment

The search includes immunological agents, enzyme inhibitors, and soluble competitive inhibitors. Now, a new study published on the preprint server bioRxiv in October 2020 provides preliminary evidence that small molecules can inhibit viral entry by inhibiting spike-ACE2 attachment.

26 Oct 2020

New inhibitor of SARS-CoV-2 RNA translation

As the search for effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibitors continues, a recent study by Yale University School of Medicine researchers published on the preprint server bioRxiv in October 2020 reports the inhibitory effect of the drug merofloxacin on frameshifting during SARS-CoV-2 replication.

26 Oct 2020